PTC299

Identification

Name
PTC299
Accession Number
DB05173
Type
Small Molecule
Groups
Investigational
Description

PTC299 is a novel, orally administered small-molecule designed to inhibit the production of vascular endothelial growth factor (VEGF) in tumors. Overexpression of VEGF plays a key role in multiple diseases including cancer and macular degeneration. PTC299 was discovered through PTC's GEMS technology by targeting the post-transcriptional processes that regulate VEGF formation, and is currently being developed for the treatment of cancer.

Synonyms
Not Available
Categories
UNII
Not Available
CAS number
Not Available
Weight
Not Available
Chemical Formula
Not Available
InChI Key
Not Available
InChI
Not Available
IUPAC Name
Not Available
SMILES
Not Available

Pharmacology

Indication

Investigated for use/treatment in cancer/tumors (unspecified) and solid tumors.

Pharmacodynamics

PTC299 demonstrated a broad range of activity in blocking VEGF synthesis in multiple tumor types, including breast, cervical, colorectal, fibrosarcoma, gastric, lung, melanoma, neuroblastoma, ovarian, pancreatic, prostate and renal cell cancer lines. PTC299 as a monotherapy significantly reduced VEGF concentrations in tumors and plasma, reduced tumor blood vessel density, and substantially impeded tumor progression.

Mechanism of action

PTC299 was designed to inhibit VEGF production in tumors by targeting the post-transcriptional control processes that regulate VEGF formation. Because PTC299 inhibits VEGF production, its action occurs at a different point in the VEGF pathway than therapies, such as AvastinĀ® or SutentĀ®. PTC299 may be active both as a single agent or when used in combination with other anti-angiogenic agents or with chemotherapy agents for the treatment of cancers.

Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteraction
(4R)-limoneneThe risk or severity of adverse effects can be increased when PTC299 is combined with (4R)-limonene.
16-BromoepiandrosteroneThe risk or severity of adverse effects can be increased when PTC299 is combined with 16-Bromoepiandrosterone.
19-norandrostenedioneThe risk or severity of adverse effects can be increased when PTC299 is combined with 19-norandrostenedione.
5-androstenedioneThe risk or severity of adverse effects can be increased when PTC299 is combined with 5-androstenedione.
AceclofenacThe risk or severity of adverse effects can be increased when PTC299 is combined with Aceclofenac.
AcemetacinThe risk or severity of adverse effects can be increased when PTC299 is combined with Acemetacin.
AlclofenacThe risk or severity of adverse effects can be increased when PTC299 is combined with Alclofenac.
AldosteroneThe risk or severity of adverse effects can be increased when PTC299 is combined with Aldosterone.
AlminoprofenThe risk or severity of adverse effects can be increased when PTC299 is combined with Alminoprofen.
AndrographolideThe risk or severity of adverse effects can be increased when PTC299 is combined with Andrographolide.
Food Interactions
Not Available

References

General References
Not Available
External Links
PubChem Substance
347909999

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedTreatmentMetastatic Breast Cancer (MBC)1
1SuspendedTreatmentCancer, Advanced1
2TerminatedTreatmentNeurofibromatosis 21

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
Not Available
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Taxonomy

Classification
Not classified

Drug created on October 21, 2007 16:24 / Updated on October 01, 2018 13:59